Home Biosciences
Home Biosciences was a Paris-based biotech venture builder creating portfolio companies (One Biosciences, Sequantrix, Apikal Therapeutics) via a hub-and-spoke model. Founded in 2020 with $15M from Redmile Group and Sofinnova Partners, it became dormant in January 2025.
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Home Biosciences does
Home Biosciences was a Paris-based biotech venture builder founded in 2020 by David Schilansky and Magali Richard, positioned as the first dedicated biotech venture builder in Continental Europe. It operated an asset-centric, hub-and-spoke model — identifying academic science, assembling dedicated project teams, providing operational support and seed funding, and growing standalone biotech companies toward independent commercialization. Over five years it created three portfolio companies: One Biosciences SAS (single-cell AI-driven molecular profiling for advanced cancer care, co-founded with Institut Curie and Céline Vallot), Sequantrix GmbH (fibrotic disease drug discovery leveraging one of the world's largest human multi-modal single-cell datasets, co-founded with researchers from RWTH Aachen), and Apikal Therapeutics SAS (co-founded with Necker Hospital's Guillaume Canaud and CNRS's Laurent Micouin). The firm raised a single $15 million Seed round in November 2021, co-led by Redmile Group and Sofinnova Partners, with no subsequent funding rounds disclosed.
The underlying technology stack spans proprietary single-cell wet-lab and computational pipelines (One Biosciences) and a large multi-modal single-cell fibrosis dataset (Sequantrix). The business model was equity-value creation through venture portfolio ownership rather than product revenue or licensing royalties at the parent level; the parent did not sell products or services directly. In January 2025, Home Biosciences ended day-to-day operations and transitioned to dormant, non-operating status with no Board of Directors, refocusing exclusively on supporting the three portfolio companies it had co-founded.
Home Biosciences firmographics
Firmographics- Name
- Home Biosciences
- Legal name
- Home Biosciences SAS
- Website
- https://homebiosciences.com/
- Company type
- Private
- Founded year
- 2019
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- Home Biosciences was a Paris-based biotech venture builder creating portfolio companies (One Biosciences, Sequantrix, Apikal Therapeutics) via a hub-and-spoke model. Founded in 2020 with $15M from Redmile Group and Sofinnova Partners, it became dormant in January 2025.
- Ownership category
- akta.pro rank
Home Biosciences industry classification
Industry- Product category
- Biotech Venture Building
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industry
- Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)
Keywords
Where Home Biosciences is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Home Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Equity value creation through venture portfolio: Home Biosciences generates value through equity ownership in the companies it co-founds and builds. As a venture builder, the company creates new biotech companies from scratch and builds value through their development, likely through equity appreciation and eventual exits.
- Operational support and funding: Provides funding and operational support to portfolio companies, creating value through successful company development and scale-up.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Home Biosciences product offering
Product offeringCore offering
Home Biosciences was a European biotech venture builder that identified promising academic science, co-founded dedicated biotech companies, and provided them with funding, operational support, and dedicated project teams under a hub-and-spoke operating model. In five years it built three companies from scratch: One Biosciences (single-cell and AI-based molecular profiling for cancer care), Sequantrix (fibrotic disease drug discovery using a large multi-modal single-cell dataset), and Apikal Therapeutics (therapeutics co-founded with academic partners). The company ended day-to-day operations in January 2025 and transitioned to non-operating/dormant status.
Product overview
Home Biosciences was the first and leading biotech company focused on venture building in Continental Europe, operating as a hub-and-spoke model. The company functioned as a venture builder that created and scaled biotech companies from scratch. It operated from 2020 until January 2025 when it ended day-to-day operations and moved to non-operating mode, now focusing on building value for its portfolio companies. The three venture companies it created are: One Biosciences (molecular profiling/cancer care using single-cell and AI technology), Sequantrix (fibrotic disease drug discovery using multi-modal single-cell datasets), and Apikal Therapeutics (co-founded with academic partners from Necker Hospital and CNRS).
Differentiator
Problem solved
Functional benefit
Products and services
- One Biosciences One Biosciences is a Techbio company in the molecular profiling space that uses single-cell-based proprietary technology, including AI-driven analysis applied to clinical specimens, to create a functional profile of a given patient's tumor at a given point in time, with potential to deconvolute complex biology in advanced cancer.
- Sequantrix Sequantrix leverages one of the world's largest human multi-modal, single-cell datasets in fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to clinical proof of concept, regrouping leading pioneers in fibrosis research, clinical care and computational science.
- Apikal Therapeutics Apikal Therapeutics is a venture company co-founded by Home Biosciences with Guillaume Canaud (Necker Hospital) and Laurent Micouin (CNRS), focused on developing innovative therapeutic approaches.
Quantifiable outcome
- Built three companies from scratch in five years
- +1 more outcomes
Companies that use Home Biosciences
Customer profileSegments2 records
Ideal customer profiles2 records
Home Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Home Biosciences partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core.
- Institut CuriecoreCo-founding partner for One Biosciences alongside Céline Vallot. Institut Curie is a leading French cancer research institute providing scientific expertise and research capabilities.
- Céline VallotcoreCo-founder of One Biosciences with Home Biosciences and Institut Curie. Scientist bringing expertise in molecular profiling and cancer research.
- Rafael KramanncoreCo-founder of Sequantrix. MD, PhD, bringing clinical and scientific expertise in fibrosis research.
- Rebekka K. SchneidercoreCo-founder of Sequantrix. MD, PhD, contributing expertise in fibrosis research and clinical care.
- Michael RheinneckercoreCEO of Sequantrix. Brings executive leadership and operational expertise to the venture.
- Guillaume CanaudcoreCo-founder of Apikal Therapeutics. Physician at Necker Hospital bringing clinical expertise and medical insight.
- Laurent MicouincoreCo-founder of Apikal Therapeutics. Researcher at CNRS (French National Centre for Scientific Research) providing scientific foundation.
- Necker HospitalcoreAcademic medical institution affiliated with Guillaume Canaud for Apikal Therapeutics co-founding.
- CNRS (French National Centre for Scientific Research)corePremier French research institution affiliated with Laurent Micouin for Apikal Therapeutics co-founding.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Home Biosciences competitors and assessment
Company assessmentDirect peers
- Roivant Sciences: Roivant is an asset-centric biotech holding company that launches and operates multiple subsidiary biotechs (Vants), directly mirroring Home Biosciences' hub-and-spoke venture builder model in the biotech space.
- PureTech Health: PureTech is a clinical-stage biotech company that founded and develops multiple therapeutic programs from internal R&D, functioning as a European/UK biotech venture builder and incubator similar to Home Biosciences.
- Medicxi: Medicxi is a European biotech-focused venture capital firm that incubates and builds single-asset or asset-centric biotech companies, sharing Home Biosciences' model of creating dedicated biotech vehicles around specific scientific programs.
- Apollo Therapeutics: Apollo Therapeutics is a UK-based biotech venture builder formed by AstraZeneca, GSK, J&J and others to translate academic research into new biotech companies, directly comparable to Home Biosciences' academic-partnered venture creation model.
- Arix Bioscience (now ITC Therapeutics): Arix Bioscience was a London-listed biotech venture builder focused on creating and developing multiple biotech companies, closely paralleling Home Biosciences' model of portfolio-based biotech company creation in Europe.
Broad incumbents
- Flagship Pioneering: Flagship Pioneering is the largest and most established biotech venture builder, having created companies like Moderna. It pioneered the asset-centric creation model that inspired Home Biosciences, though at much larger scale.
- BridgeBio Pharma: BridgeBio uses an asset-centric model to develop multiple therapeutic programs for genetic diseases. While broader and more clinically advanced than Home Biosciences, it shares the hub-and-spoke philosophy of focused, dedicated teams per program.
Emerging players
- Vesalius Therapeutics: Vesalius is a Flagship-founded biotech company applying a venture builder approach to common disease drug discovery, with comparable academic-partnered, asset-centric philosophy to Home Biosciences.
- Newleos Therapeutics: Newleos Therapeutics is an early-stage biotech venture created by a European team to develop neuroscience therapeutics from academic research, sharing Home Biosciences' model of building single-program biotechs around founder-scientist expertise.
- STORM Therapeutics: STORM Therapeutics is a UK-based biotech spun out of Cambridge research to develop RNA-modifying enzyme inhibitors, comparable to Home Biosciences' portfolio companies that were built around specific academic discoveries.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Home Biosciences social profiles
Digital presenceHome Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Home Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Home Biosciences subsidiaries and ownership
Company hierarchySubsidiaries3 records
Home Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Home Biosciences M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Home Biosciences
What does Home Biosciences do?
Home Biosciences was a European biotech venture builder that identified promising academic science, co-founded dedicated biotech companies, and provided them with funding, operational support, and dedicated project teams under a hub-and-spoke operating model. In five years it built three companies from scratch: One Biosciences (single-cell and AI-based molecular profiling for cancer care), Sequantrix (fibrotic disease drug discovery using a large multi-modal single-cell dataset), and Apikal Therapeutics (therapeutics co-founded with academic partners). The company ended day-to-day operations in January 2025 and transitioned to non-operating/dormant status.
Is Home Biosciences a public or private company?
Home Biosciences is a private company. It is classified as venture growth investor backed and is currently closed.
When was Home Biosciences founded?
Home Biosciences was founded in 2019. It employs 1 to 10 people.
Where is Home Biosciences based?
Home Biosciences is headquartered in Paris, France, in the Europe region.
How does Home Biosciences make money?
Two revenue lines are on record. Equity value creation through venture portfolio is the primary driver. The others are operational support and funding.
Who are Home Biosciences's main competitors?
Direct peers on record are Roivant Sciences, PureTech Health, Medicxi, Apollo Therapeutics and Arix Bioscience (now ITC Therapeutics). Broad incumbents are Flagship Pioneering and BridgeBio Pharma. Emerging players are Vesalius Therapeutics, Newleos Therapeutics and STORM Therapeutics.
Does Home Biosciences have an API?
No public API is recorded for Home Biosciences.
What industry is Home Biosciences in?
Home Biosciences's product category is Biotech Venture Building. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAGAGAE, Process Development & Tech Transfer (Upstream/Downstream/MSAT). Its NAICS code is 541714 and its SIC code is 8731.